NEOTORCH

NCT04158440 📎

Regimen

Experimental: neoadj toripalimab+chemo → adjuvant toripalimab
Control: chemo

Population

Chinese resectable stage II-III NSCLC

Key finding

EFS HR 0.40 (0.28-0.57); MPR 48.5% vs 8.4%; Chinese PD-1 perioperative success

Source: PMID 38227033

Timeline

Enrollment start: 2020-04-07 📎

Guideline citations

CSCO NSCLC 2025 ⚠️ OCR source